Use of incretin agents and risk of pancreatic cancer: a population-based cohort study-Reference-Cited by-同舟云学术

Use of incretin agents and risk of pancreatic cancer: a population-based cohort study

Published:2016-01-08 Issue:3 Volume:18 Page:258-265
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Knapen L. M.¹,van Dalem J.¹,Keulemans Y. C.²,van Erp N. P.³,Bazelier M. T.⁴,De Bruin M. L.⁴,Leufkens H. G. M.⁴,Croes S.¹,Neef C.¹⁵,de Vries F.¹⁴⁵⁶,Driessen J. H. M.¹⁴⁵

Affiliation:

1. Division of Clinical Pharmacy & Toxicology; Maastricht University Medical Centre; Maastricht The Netherlands

2. Department of Gastroenterology; Zuyderland; Heerlen Netherlands

3. Department of Pharmacy; Radboud University Medical Centre; Nijmegen The Netherlands

4. Division of Pharmacoepidemiology and Clinical Pharmacology; Utrecht Institute for Pharmaceutical Sciences; Utrecht The Netherlands

5. Care and Public Health Research Institute (CAPHRI); Maastricht The Netherlands

6. MRC Lifecourse Epidemiology Unit; Southampton General Hospital, University of Southampton; Southampton UK

Funder

ZonMw

College voor Zorgverzekeringen

Royal Dutch Pharmacists Association (KNMP)

EU Innovative Medicines Initiative (IMI)

Seventh Framework Programme

Ministerie van Volksgezondheid, Welzijn en Sport

GlaxoSmithKline

Pfizer

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12605/fullpdf

Reference47 articles.

1. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits;Drucker;Diabetes Care,2010

2. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?;Butler;Diabetes Care,2013

3. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database;Raschi;Acta Diabetol,2013

4. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats;Farilla;Endocrinology,2002

5. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits;Ryder;Diabet Med,2013

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MetALD: Does it require a different therapeutic option?;Hepatology;2024-05-31

2. Consistency between the National Patient Register and the Swedish Cancer Register;Pharmacoepidemiology and Drug Safety;2024-03-21

3. Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients With Type 2 Diabetes;JAMA Network Open;2024-01-04

4. Association between sodium-glucose cotransporter 2 inhibitors and pancreatic cancer in the Japanese working-age population;Int. Journal of Clinical Pharmacology and Therapeutics;2023-11-01

5. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis;International Journal of Clinical Pharmacy;2023-03-28